UNSPSC 51291505: Cyclazodone

This classification denotes a cns stimulant with the molecular formula C12H12N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O8U55ZRL9K, chemically known as 4(5h)-oxazolone, 2-(cyclopropylamino)-5-phenyl- (9ci) but generally known as cyclazodone, which bears US NIH Compound Identifier 26701. European Medicines Agency schedules Cyclazodone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06844MIG.

UNSPSC 51291505 Cyclazodone (Commodity) covers pharmaceutical products and related systems, though recent state and local solicitations under this code do not focus on cyclazodone itself. Instead, buying activity reflects procurement of pharmaceutical supply chains, naloxone systems, generic multi-source pharmaceuticals, and over-the-counter products through competitive bidding and cooperative purchasing frameworks. State and local governments—including county health departments, state health and human services agencies, and multistate cooperative purchasing alliances—use this code to solicit manufacturers and distributors for pharmaceutical inventories serving community health programs, pharmacy benefit initiatives, and employee health plans. The scope spans product procurement with specific National Drug Code requirements, supply chain compliance certifications (FDA registration, cGMP, Drug Supply Chain Security Act compliance), insurance and liability coverage, and coordination with authorized wholesalers for distribution and quarterly or ongoing deliveries.

Recent activity centers in Florida and Minnesota through early 2026. Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building through July 26, 2026. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across state and local government facilities in Minnesota and Oregon, requiring responses by March 26, 2026, with contracts effective July 1, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, reflecting exploratory procurement of direct-to-manufacturer pharmaceutical supply models outside traditional pharmacy benefit manager arrangements.